GlassScriptPhysician profile
Alexandra Pierce
NPI 1225515158
$2,968.10
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $440 · 2022: $1,614 · 2023: $610 · 2024: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $914.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $913.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $538.63 | 2021-2023 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $519.24 | 2021-2024 | Farxiga, Fasenra, Airsupra |
| Abbvie INC. | $371.37 | 2022-2024 | |
| Glaxosmithkline, LLC. | $252.47 | 2022-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $206.99 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Sunovion Pharmaceuticals INC. | $172.27 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $169.94 | 2022-2024 | Caplyta |
| Pfizer INC. | $86.82 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $73.66 | 2021-2022 | |
| Exact Sciences Corporation | $71.98 | 2023-2024 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $65.75 | 2022 | |
| Amgen INC. | $46.82 | 2022-2024 | Otezla, Repatha |
| Sanofi Pasteur INC. | $41.88 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $41.85 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.59 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.57 | 2021-2022 | |
| Medtronic, INC. | $32.57 | 2022-2023 | Vanta Adaptivestim |
| Idorsia Pharmaceuticals US INC | $31.24 | 2023 | Quviviq |
| Eisai INC. | $29.71 | 2021 | |
| Amarin Pharma, INC. | $20.98 | 2021 | |
| Kaleo, INC. | $18.34 | 2022 | |
| Astellas Pharma US INC | $18.21 | 2022 | |
| Sumitomo Pharma America, INC. | $17.73 | 2023 | Gemtesa |
| Corcept Therapeutics | $16.95 | 2022 | |
| Corium, LLC | $15.77 | 2022 | |
| Novartis Pharmaceuticals Corporation | $15.10 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Pierce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.